Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer

TY - JOUR

T1 - Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer

AU - Ribi, K.

AU - Aldridge, J.

AU - Phillips, K-A

AU - Thompson, A.

AU - Harvey, V.

AU - Thuerlimann, B.

AU - Cardoso, F.

AU - Pagani, O.

AU - Coates, A. S.

AU - Goldhirsch, A.

AU - Price, K. N.

AU - Gelber, R. D.

AU - Bernhard, J.

AU - IBCSG, Big I-98 Collaborative Grp

PY - 2012

Y1 - 2012

N2 - BACKGROUND: In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF).METHODS: One hundred postmenopausal women, randomised to receive 5 years of adjuvant tamoxifen, letrozole, or a sequence of the two, completed self-reported measures on SCF, psychological distress, fatigue, and quality of life during the fifth year of trial treatment (year 5) and 1 year after treatment completion (year 6). Changes between years 5 and 6 were evaluated using the Wilcoxon signed-rank test. Subjective cognitive function and its correlates were explored.RESULTS: Subjective cognitive function and the other patient-reported outcomes did not change significantly after cessation of endocrine therapy with the exception of improvement for hot flushes (P = 0.0005). No difference in changes was found between women taking tamoxifen or letrozole. Subjective cognitive function was the only psychosocial outcome with a substantial correlation between year 5 and 6 (Spearman's R = 0.80). Correlations between SCF and the other patient-reported outcomes were generally low.CONCLUSION: Improved objective cognitive function but not SCF occur following cessation of adjuvant endocrine therapy in the BIG 1-98 trial. The substantial correlation of SCF scores over time may represent a stable attribute. British Journal of Cancer (2012) 106, 1618-1625. doi:10.1038/bjc.2012.156 www.bjcancer.com Published online 24 April 2012 (C) 2012 Cancer Research UK

AB - BACKGROUND: In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF).METHODS: One hundred postmenopausal women, randomised to receive 5 years of adjuvant tamoxifen, letrozole, or a sequence of the two, completed self-reported measures on SCF, psychological distress, fatigue, and quality of life during the fifth year of trial treatment (year 5) and 1 year after treatment completion (year 6). Changes between years 5 and 6 were evaluated using the Wilcoxon signed-rank test. Subjective cognitive function and its correlates were explored.RESULTS: Subjective cognitive function and the other patient-reported outcomes did not change significantly after cessation of endocrine therapy with the exception of improvement for hot flushes (P = 0.0005). No difference in changes was found between women taking tamoxifen or letrozole. Subjective cognitive function was the only psychosocial outcome with a substantial correlation between year 5 and 6 (Spearman's R = 0.80). Correlations between SCF and the other patient-reported outcomes were generally low.CONCLUSION: Improved objective cognitive function but not SCF occur following cessation of adjuvant endocrine therapy in the BIG 1-98 trial. The substantial correlation of SCF scores over time may represent a stable attribute. British Journal of Cancer (2012) 106, 1618-1625. doi:10.1038/bjc.2012.156 www.bjcancer.com Published online 24 April 2012 (C) 2012 Cancer Research UK

U2 - 10.1038/bjc.2012.156

DO - 10.1038/bjc.2012.156

M3 - Article

C2 - 22531635

SN - 0007-0920

VL - 106

SP - 1618

EP - 1625

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 10

ER -